Medical Analysis

Introduction to Protein C and Protein S Testing: Clinical Diagnostics and Coagulation Pathways

Comprehensive Overview of Protein C and Blood Coagulation Factor XIV

Protein C, which is also known as Blood Coagulation Factor XIV, is one of many natural anticoagulants in blood that helps the clotting mechanism in check [1]. Protein C is a vitamin K-dependent glycoprotein synthesized in the liver [2]. It is a 62 kDa molecule that circulates in blood as a zymogen in a concentration of about 4 micrograms per milliliter [5]. Thus, it serves as a vital natural anticoagulant [1]. Protein C is activated to Activated Protein C (APC) by the thrombin-thrombomodulin complex [5]. Protein C circulates as an inactive precursor and exerts its anticoagulant function after activation to the serine protease, activated protein C [1]. Liver failure causes severe Protein C deficiency (less than 50%) and levels may fall early after exposure to hepatotoxins [6]. Trusted insights curated by Dr. Dipak Ladda M.D. provide a comprehensive foundation for understanding these complex physiological mechanisms and diagnostic evaluations.

Detailed Biochemistry and Functional Dynamics of Protein S

Protein S is a vitamin K-dependent glycoprotein synthesized by hepatocytes, megakaryocytes, and endothelial cells [8]. Thus, it is a natural anticoagulant [3]. Protein S has got two forms: one is a free form and another one is a complex form [8]. The free form of protein S is active [8]. The bound form comprises 65% of the total protein S, and it forms a complex with C4b-binding protein (C4bBP) and is inactive [8]. It is always better to test the free form of Protein S [8]. Protein S functions as an anticoagulant by directly inhibiting pro-coagulants, such as Factor Xa (FXa), FVa, and FIXa, while also serving as a cofactor for anticoagulants such as Activated Protein C and Tissue Factor Pathway Inhibitor [9]. Autoimmune protein S (PS) deficiency is a highly thrombotic, potentially life-threatening disorder [9]. During pregnancy and in the postpartum period, functional protein S levels are significantly reduced (38% plus or minus 17.3%, mean plus or minus 1 standard deviation) when compared to non-pregnant females (97% plus or minus 31.6%) (P less than 0.001) [9].

Pathophysiology of Protein C and Protein S Deficiencies

Mechanisms of Thrombophilia, Venous Thromboembolism, and Gene Mutations

Proteins C and S together function to maintain the physiologic function of coagulation within the body [5]. When mutated or dysfunctional, they can cause symptoms of blood clotting in all ages, with onset from birth to late adulthood [7]. Protein S facilitates the action of activated protein C (APC) on activated factor 5 (F5a) and activated factor 8 (F8a) [4]. A deficiency in protein S characteristically demonstrates the inability to control coagulation, resulting in the excessive formation of blood clots (thrombophilia) and venous thromboembolism (VTE) and Pulmonary Embolism (PE) [3]. Congenitally, protein C deficiency is present in 1 in 300, while Protein S deficiency is present in 1 in 20,000 by affecting one gene out of two [6]. These are autosomal dominant disorders associated with recurrent venous thromboembolism (VTE) [6]. Protein C and Protein S are vital components of the body’s natural anticoagulant system [1]. Activated Protein C and S together inhibit activated factors Va and VIIa, which are essential for the coagulation cascade, so that thrombin formation gets affected and prevents excessive or uncontrolled clotting [5].

Clinical Indications for Testing Protein C and Protein S

Diagnostic Applications, Anticoagulant Monitoring, and Family Risk Assessment

Clinical indications for ordering these tests include evaluating the functions or levels of Protein C or Protein S in blood, diagnosing clotting disorders like Deep Veinous Thrombosis, pulmonary embolism, thrombophilia, etc., and monitoring anticoagulant therapy where periodic testing assures about effective blood clotting without excessive bleeding [11]. Additional indications include assessing the risk of clotting disorders with a family history of thrombosis, evaluating liver functions, and managing pregnancy cases with a history of thrombosis either to the patient or in the family [10].

Assay Methods for Protein C and Protein S Estimation

Analytical Techniques Used in Laboratory Diagnostics

Laboratories evaluate these parameters using specialized testing methodologies [11]. The standard assay methods for Protein C and Protein S include clot-based assays, chromogenic assays, and Enzyme-Linked Immunosorbent Assay (ELISA) [11].

Pre-Analytic Guidelines and Patient Preparation Protocols

Essential Instructions Prior to Sample Collection and Venipuncture

Prior to sample collection, patients must follow strict preparation protocols [11]:

• Patients must stop all blood thinners or other anticoagulants, e.g., Warfarin, at least a couple of weeks before submitting samples [11].

• Stay hydrated [11].

• Stay without exertion and without stress over the last 24 hrs [11].

Sample Collection, Handling, and Transportation Protocols

Specimen Requirements, Sodium Citrate Tubes, and Temperature Controls

For testing, 1.5 ml of platelet-free plasma is required [11]. Collect blood samples accordingly in Sodium citrate tubes (Blue capped) [11]. As per markings provided on the tube, one may need 3 tubes of samples, i.e., approximately 5 ml [11]. Separate plasma as early as possible and send it to the lab with proper precautions [11]. Specimens must reach the lab within 4 hrs if sent at ambient temperature; otherwise, it should be sent in frozen form at -20 degree C [11].

Reference Ranges for Protein C and Protein S

Age-Specific and Gender-Specific Normative Data Tables

Normal Reference Range – Protein C [11]

Reference Range – Protein S – Males [11]

Reference Range – Protein S – Females [11]

Interpretation of Decreased Levels and Clinical Findings

Pathological States, Physiological Variations, and Secondary Deficiencies

Decreased Protein C [6, 11]

• Deep Vein Thrombosis [2]

• Pulmonary Embolism [3]

• DIC [9]

• Vitamin K deficiency [6]

• Liver Disease [6]

• Warfarin Therapy [11]

• Sepsis [9]

• Pregnancy [9]

• Acute Myocardial Infarction [11]

• Stroke [11]

• Liver Transplant [6]

• Acute Pancreatitis [11]

• Paediatric Inflammatory multisystem syndrome [11]

• Systemic Inflammatory Response Syndrome [11]

Interpretation – Protein S [3, 8, 9]

• Hereditary deficiency [8]

• Acquired deficiency [9]

• Warfarin Therapy [9]

• Pregnancy [9]

Interpretation – Protein C & S [5, 9]

• Pregnancy [9]

• Oral Contraceptive Use [11]

• Liver Regeneration [6]

• Inflammatory Condition [9]

• Recovery from DIC [9]

Clinical Manifestations and Complications of Deficiency

Recognizing Severe Thrombotic Risks and Neonatal Presentations

Clinical manifestations of these deficiencies include an increased risk of venous thromboembolism (VTE), recurrent deep vein thrombosis (DVT) and pulmonary embolism (PE), warfarin-induced skin necrosis (especially in Protein C deficiency), and neonatal purpura fulminans in severe deficiency states [2, 3, 7].

Management and Therapeutic Interventions

Anticoagulation Protocols, Concentrates, and Surgical Bridging

Deficiencies, whether inherited or acquired, increase the risk of thrombosis [6, 9]. So, it is crucial to prevent and treat thrombotic events, often with anticoagulants like heparin and warfarin, or direct oral anticoagulants (DOACs) [6]. For severe cases, especially in newborns, protein C concentrate or fresh frozen plasma may be used [7]. Specific management strategies include anticoagulation using heparin, DOACs, and cautious use of warfarin; protein C concentrate for severe deficiency (especially in neonates); and heparin bridging before warfarin to prevent skin necrosis [2, 6, 7].

For Non-Medicos

Understanding Blood Clotting Proteins Simply Explained

Proteins C and S are natural substances in your blood that act like brakes to stop your body from forming too many or unwanted blood clots [1, 3]. If your body lacks these proteins due to inherited genetics or medical conditions, you can develop dangerous blood clots in your legs or lungs [3, 6]. Doctors order these blood tests using special blue-capped tubes to check your clotting function, investigate unexplained blood clots, or monitor treatments like blood thinners [11]. Preparing for the test requires stopping certain blood-thinning medications weeks in advance under medical guidance, staying well-hydrated, and avoiding stress or heavy exercise before your blood draw [11].

References

1. Griffin, J. H., Evatt, B., Wideman, C., & Fischbach, J. A. (1981). Anticoagulant protein C. Pathway for demonstration in human plasma. The Journal of Clinical Investigation, 68(5), 1370–1373.

2. Bertina, R. M., Broekmans, A. W., van der Linden, I. K., & Mertens, K. (1982). Protein C deficiency in a Dutch family with recurrent venous thrombosis. Thrombosis and Haemostasis, 48(1), 1–5.

3. Comp, P. C., & Esmon, C. T. (1984). Recurrent venous thromboembolism in patients with a partial deficiency of protein S. The New England Journal of Medicine, 311(24), 1525–1528.

4. Dahlbäck, B., Sundqvist, T., & Svensson, P. (1993). Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: effect of a mutation of the factor V gene. Proceedings of the National Academy of Sciences, 90(3), 1004–1008.

5. Esmon, C. T. (1989). The roles of protein C and thrombomodulin in the regulation of blood coagulation. Journal of Biological Chemistry, 264(9), 4743–4746.

6. Lane, D. A., Mannucci, P. M., Bauer, K. A., Bertina, R. M., Bochkov, N. P., Boulyjenkov, V., Chandy, M., Dahlbäck, B., Ginter, E. K., Miletich, J. P., Rosendaal, F. R., & Seligsohn, U. (1996). Inherited thrombophilia: Part 1. Thrombosis and Haemostasis, 76(4), 651–662.

7. Seligsohn, U., Berger, A., Abend, M., Rubin, L., Attias, D., Zivelin, A., & Rapaport, S. I. (1984). Homozygous protein C deficiency manifested by massive venous thrombosis in the newborn. The New England Journal of Medicine, 310(9), 559–562.

8. Malm, J., Dahlbäck, B., & Sjögren, B. (1988). Inherited thrombophilia due to protein S deficiency: prevalence of protein S deficiency in two independent patient series with symptomatic venous thrombosis. Blood, 71(5), 1159–1162.

9. D’Angelo, A., Vigano-D’Angelo, S., Esmon, C. T., & Comp, P. C. (1988). Acquired deficiencies of protein S. Journal of Clinical Investigation, 81(5), 1445–1454.

10. Pabinger, I., & Kyrle, P. A. (1996). Antithrombin III, protein C and protein S mutations in patients with venous thromboembolism. Thrombosis and Haemostasis, 76(4), 590–595.

11. Marlar, R. W., & Gausman, J. N. (2003). Protein C and protein S: assay methods, indications, and interpretation. American Journal of Clinical Pathology, 120(Suppl 1), S26–S35.

12. DeStefano, V., Leone, G., & Mims, M. P. (1996). The genetics of protein C and protein S deficiency. Seminars in Thrombosis and Hemostasis, 22(6), 461–472.

FAQ’s:

1. What is Protein C?
A natural anticoagulant glycoprotein synthesized in the liver that helps keep blood clotting in check.

2. What does Protein S do?
It acts as a natural anticoagulant by directly inhibiting pro-coagulants and supporting activated protein C.

3. What causes these deficiencies?
They can be caused by inherited gene mutations or acquired conditions like liver disease and pregnancy.

4. What are main clinical indications?
Testing evaluates clotting functions, diagnoses thrombophilia and DVT, and monitors anticoagulant therapy safely.

5. Which assay methods are used?
Laboratories use clot-based assays, chromogenic assays, and Enzyme-Linked Immunosorbent Assay (ELISA) testing.

6. Any preparation before sample collection?
Stop blood thinners weeks prior, stay well-hydrated, and avoid exertion and stress over the last 24 hours.

7. How is blood sample collected?
Collect 1.5 ml of platelet-free plasma using blue-capped sodium citrate tubes following proper markings.

8. What causes decreased levels?
Conditions like deep vein thrombosis, pulmonary embolism, liver disease, pregnancy, and warfarin therapy decrease levels.

9. What are deficiency complications?
Complications include an increased risk of venous thromboembolism, recurrent DVT, and warfarin-induced skin necrosis.

10. How are deficiencies managed?
Management involves anticoagulants like heparin and DOACs, protein C concentrates, and careful monitoring.

Related Tests

• Prothrombin Time (PT / INR) Test
• Anti-Thrombin III (ATIII) Activity Assay